S. M. Aarde, In vivo potency and efficacy of the novel cathinone alphapyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: selfadministration and locomotor stimulation in male rats, Psychopharmacol. Berl, vol.232, issue.16, pp.3045-3055, 2015.

R. Abbott and D. E. Smith, The new designer drug wave: a clinical, toxicological, and legal analysis, J. Psychoact. Drugs, vol.47, issue.5, pp.368-371, 2015.

P. Adamowicz, Analysis of MDPV in bloodedetermination and interpretation, J. Anal. Toxicol, vol.37, issue.5, pp.308-312, 2013.

S. Andrabi, New drugs of abuse and withdrawal syndromes, Emerg. Med. Clin. North Am, vol.33, issue.4, pp.779-795, 2015.

L. Ashrafioun, Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones, J. Psychoact. Drugs, vol.48, issue.5, pp.632-642, 2014.

M. H. Baumann, J. S. Partilla, K. R. Lehner, E. B. Thorndike, A. F. Hoffman et al., Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products, Neuropsychopharmacology, vol.38, issue.4, pp.552-562, 2013.

M. H. Baumann, J. S. Partilla, and K. R. Lehner, Psychoactive "bath salts": not so soothing, Eur. J. Pharmacol, vol.698, issue.1e3, pp.1-5, 2013.

M. H. Baumann, Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs, Curr. Top. Behav. Neurosci, vol.32, 1967.

B. Byrska, R. Stanaszek, and D. Zuba, Alpha-PVP as an active component of herbal highs in Poland between, Drug Test. Anal, vol.9, issue.8, pp.1267-1274, 2013.

K. Cameron, Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter, Psychopharmacol. Berl, vol.227, issue.3, pp.493-499, 2013.

J. H. Cheong, Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents, Psychopharmacol. Berl, vol.234, issue.5, pp.857-867, 2017.

M. Coppola and R. Mondola, 4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online, Toxicol. Lett, vol.3, issue.1, pp.12-15, 2012.

O. Cottencin, B. Rolland, and L. Karila, New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature, Curr. Pharm. Des, vol.20, issue.25, pp.4106-4111, 2014.

C. Crespi, Flakka-induced Prolonged Psychosis. Case Rep Psychiatry, p.3460849, 2016.

, Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones into Schedule I in, 2017.

K. N. Ellefsen, M. Concheiro, and M. A. Huestis, Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases, Drug Metab. Rev, vol.48, issue.2, pp.237-265, 2016.

E. Emcdda, Monitoring Centre for Drugs and Drug Addiction, EMCDDAeeuropol Joint Report on a New Psychoactive Substance: MDPV (3,4-methylenedioxypyrovalerone), 2014.

E. Emcdda, Monitoring Centre for Drugs and Drug Addiction, EMCDDAeeuropol Joint Report on a New Psychoactive Substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (a-PVP), 2015.

, Rapport europ een sur les drogues 2016. Tendances et evolutions. Office des publications de l'Union europ eenne, Luxembourg. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction, Observatoire europ een des drogues et des toxicomanies, 2016.

, pentan-1-one (a-pyrrolidinovalerophenone, a-PVP)

, European Monitoring Centre for Drugs and Drug Addiction, EMCDDA, 2017.

. Erowid, Any Reports with Alpha-PVP. [Online] Erowid Experience Vault, 2017.

J. Fratantonio, L. Andrade, and M. Febo, Designer drugs: a synthetic catastrophe, J. Reward Defic. Syndr, vol.1, issue.2, pp.82-86, 2015.

B. A. Froberg, Acute methylenedioxypyrovalerone toxicity, J. Med. Toxicol, vol.11, issue.2, pp.185-194, 2015.

B. M. Gannon, K. C. Rice, and G. T. Collins, Reinforcing effects of abused 'bath salts' constituents 3,4-methylenedioxypyrovalerone and alphapyrrolidinopentiophenone and their enantiomers, Behav. Pharmacol, vol.28, issue.7, pp.578-581, 2017.

G. Gavriilidis, Bath Salts" intoxication with multiorgan failure and leftsided ischemic colitis: a case report, Hippokratia, vol.19, issue.4, pp.363-365, 2015.

C. L. German, A. E. Fleckenstein, and G. R. Hanson, Bath salts and synthetic cathinones: an emerging designer drug phenomenon, Life Sci, vol.97, issue.1, pp.2-8, 2014.

C. Giese, Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in, Euro Surveill, vol.20, p.40, 2015.

R. A. Glennon, Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention, Adv. Pharmacol, vol.69, pp.581-620, 2014.

R. A. Glennon and R. Young, Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP), Brain Res. Bull, vol.126, pp.111-126, 2016.

M. Grapp, GC-MS analysis of the designer drug alphapyrrolidinovalerophenone and its metabolites in urine and blood in an acute poisoning case, Forensic Sci. Int, vol.259, pp.14-23, 2016.

R. A. Gregg, Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activator, Neuropharmacology, vol.108, pp.111-119, 2016.

, Arree^t e du 27 juillet 2012 modifiant les arre^t es du 22 f evrier 1990 fixant la liste des substances class ees comme stup efiants et la liste des substances psychotropes, JO, 2012.

A. Kaizaki, S. Tanaka, and S. Numazawa, New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron, J. Toxicol. Sci, vol.39, issue.1, pp.1-6, 2014.

L. Karila and M. Reynaud, GHB and synthetic cathinones: clinical effects and potential consequences, Drug Test. Anal, vol.3, issue.9, pp.552-559, 2011.
DOI : 10.1002/dta.210

L. Karila, Diagnosis and consequences of cocaine addiction, Curr. Med. Chem, vol.19, issue.33, pp.5612-5618, 2012.
DOI : 10.2174/092986712803988839

L. Karila, Novel psychoactive substances: a review, Presse Med, vol.44, issue.4, pp.383-391, 2015.

L. Karila, Synthetic cathinones: a new public health problem, Curr. Neuropharmacol, vol.13, issue.1, pp.12-20, 2015.
DOI : 10.2174/1570159x13666141210224137

URL : http://europepmc.org/articles/pmc4462036?pdf=render

L. Karila, The synthetic cannabinoids phenomenon, Curr. Pharm. Des, vol.22, issue.42, pp.6420-6425, 2016.
DOI : 10.2174/1381612822666160919093450

J. Knoy, B. Peterson, and F. Couper, Suspected impaired driving case involving apyrrolidinovalerophenone, methylone and ethylone, J. Anal. Toxicol, vol.38, issue.8, pp.615-617, 2014.
DOI : 10.1093/jat/bku073

URL : https://academic.oup.com/jat/article-pdf/38/8/615/18772532/bku073.pdf

P. B. Kyle, Illicit bath salts: not for bathing, J. Miss State Med. Assoc, vol.52, issue.12, pp.375-377, 2011.

K. Liveri, A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus, Forensic Sci. Int, vol.265, pp.160-165, 2016.
DOI : 10.1016/j.forsciint.2016.02.017

L. J. Marinetti, H. M. Antonides, and J. A. Marusich, Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results, J. Anal. Toxicol, vol.37, issue.3, pp.83-91, 2013.

P. Meltzer, 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors, J. Med. Chem, vol.49, issue.4, pp.1420-1432, 2006.

J. Mugele, K. Nanagas, and L. Tormoehlen, Serotonin syndrome associated with MDPV use: a case report, Ann. Emerg. Med, vol.60, pp.100-103, 2012.
DOI : 10.1016/j.annemergmed.2011.11.033

B. L. Murray, C. M. Murphy, and M. C. Beuhler, Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV), J. Med. Toxicol, vol.8, issue.1, pp.69-75, 2012.
DOI : 10.1007/s13181-011-0196-9

URL : https://link.springer.com/content/pdf/10.1007%2Fs13181-011-0196-9.pdf

B. Murray, C. Murphy, and M. Beuhler, Death following recreational use of designer drug ''bath salts'' containing 3,4-methylenedioxypyrovalerone (MDPV), J. Med. Toxicol, vol.8, pp.69-75
DOI : 10.1007/s13181-011-0196-9

URL : https://link.springer.com/content/pdf/10.1007%2Fs13181-011-0196-9.pdf

H. Nagai, Sudden death after sustained restraint following selfadministration of the designer drug alpha-pyrrolidinovalerophenone, Int. J. Cardiol, vol.172, issue.1, pp.263-265, 2014.
DOI : 10.1016/j.ijcard.2013.12.262

J. D. Nguyen, Locomotor stimulant and rewarding effects of inhaling methamphetamine, MDPV, and mephedrone via electronic cigarette-type technology, Neuropsychopharmacology, vol.41, issue.11, pp.2759-2771, 2016.
DOI : 10.1038/npp.2016.88

URL : https://www.nature.com/articles/npp201688.pdf

T. M. Penders, R. E. Gestring, and D. A. Vilensky, Excited delirium following use of synthetic cathinones (bath salts), 647e650. Potocka-Banas, vol.34, pp.553-556, 2012.

J. M. Prosser and L. S. Nelson, The toxicology of bath salts: a review of synthetic cathinones, J. Med. Toxicol, vol.8, issue.1, pp.33-42, 2012.

, Psychoactive Substances Act, PSA, p.29, 2016.

A. Rickli, M. Hoener, and M. Liechti, Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones, Eur. Neuropsychopharmacol, vol.25, issue.3, pp.365-376, 2015.

S. Rojek, New psychoactive substance alpha-PVP in a traffic accident case. Forensic Toxicol, vol.34, pp.403-410, 2016.

K. Romanek, Synthetic cathinones in Southern Germany -characteristics of users, substance-patterns, co-ingestions, and complications, Clin. Toxicol. (Phila), vol.55, issue.6, pp.573-578, 2017.

A. Salomone, Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples, Anal. Bioanal. Chem, vol.408, issue.8, pp.2035-2042, 2016.

C. W. Schindler, Pharmacological mechanisms underlying the cardiovascular effects of the "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV), Br. J. Pharmacol, vol.173, issue.24, pp.3492-3501, 2016.

A. Scocard, Synthetic cannabinoids: a new addiction matrix, Presse Med, vol.46, issue.1, pp.11-22, 2017.

K. W. Simonsen, Fatal poisoning in drug addicts in the Nordic countries in 2012, Forensic Sci. Int, vol.248, pp.172-180, 2015.

K. Sivagnanam, Cocaine-like discriminative stimulus effects of alphapyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys, Psychopharmacol. Berl, vol.14, issue.5, pp.117-127, 2013.

C. N. Stanciu, The behavioral profile of methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinopentiophenone (PVP) -a systematic review, Curr. Drug Abuse Rev, 2017.

M. Sykutera, M. Cychowska, and E. Bloch-boguslawska, A fatal case of pentedrone and alpha-pyrrolidinovalerophenone poisoning, J. Anal. Toxicol, vol.39, issue.4, pp.324-329, 2015.

K. Thomae, , p.933507, 1963.

, Decision 58/12-Inclusion of 3,4-methylenedioxypyrovalerone (MDPV) in Schedule II of the Convention on Psychotropic Substances of 1971, UNODC, vol.74, 2015.

, United Nations Office on Drugs and Crime, 2016.

M. J. Valente, 3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions, Arch. Toxicol, vol.90, issue.8, 2016.

O. M. Vallersnes, Psychosis associated with acute recreational drug toxicity: a European case series, BMC Psychiatry, vol.16, p.293, 2016.

R. Valsalan, Multi-organ dysfunction due to bath salts: are we aware of this entity?, Intern Med. J, vol.47, issue.1, pp.109-111, 2017.

A. Wander, , p.927475, 1963.

M. F. Weaver, J. A. Hopper, and E. W. Gunderson, Designer drugs 2015: assessment and management, Addict. Sci. Clin. Pract, vol.10, 2015.
DOI : 10.1186/s13722-015-0024-7

URL : https://ascpjournal.biomedcentral.com/track/pdf/10.1186/s13722-015-0024-7

C. M. White, Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications, J. Clin. Pharmacol, vol.56, issue.11, pp.1319-1325, 2016.
DOI : 10.1002/jcph.742

T. H. Wright, C. Harris, and A. Young, Two cases of disseminated intravascular coagulation due to ''bath salts'' resulting in fatalities, with laboratory confirmation, Am. J. Emerg. Med, vol.40, issue.5, pp.445-448, 2013.

J. B. Zawilska, Mephedrone and other cathinones, Curr. Opin. Psychiatry, vol.27, issue.4, pp.256-262, 2014.
DOI : 10.1097/yco.0000000000000066

J. B. Zawilska and J. Wojcieszak, Designer cathinonesean emerging class of novel recreational drugs, Forensic Sci. Int, vol.231, issue.1e3, pp.42-53, 2013.

J. Zawilska and J. Wojcieszak, Pyrrolidinophenones: a new wave of designer cathinones. Forensic Toxicol, vol.35, pp.201-216, 2017.

, United Nations Office on Drugs and Crime. World Drug Report, 2017.

, European Monitoring Centre for Drugs and Drug Addiction, European Drug Report, 2017.

P. D. Maskell, P. R. Smith, and R. Cole, Seven fatalities associated with ethylphenydate, Forensic Sci Int, vol.265, pp.70-74, 2016.

H. J. Zhu, K. S. Patrick, and . Straughn, Ethanol Interactions With Dexmethylphenidate and dl

, Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers, J Clin Psychopharmacol, vol.37, issue.4, pp.419-428, 2017.

G. P. Bailey, J. H. Ho, and S. Hudson, Nopaine no gain: Recreational ethylphenidate toxicity, ClinToxicol, vol.53, pp.498-499, 2015.

C. Parks, D. Mckeown, T. , and H. J. , A review of ethylphenidate in deaths in east and west Scotland, Forensic Sci Int, vol.257, pp.203-208, 2015.

B. Barcelo, I. Gomila, and M. C. Rotolo, Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate, Int J Legal Med, vol.131, issue.6, pp.1543-1553, 2017.

C. Lafferty, L. Smith, and A. Coull, The experience of an increase in the injection of ethylphenidate in Lothian, Scott Med Journal, vol.61, pp.74-83, 2014.

J. Krueger, H. Sachs, and . Musshoff, First detection of ethylphenidate in human fatalities after ethylphenidate intake, Forensic Sci Int, vol.243, pp.126-135, 2014.

B. Pignon, A. Muyssen, and S. Deheul, Dependence on Internet-Purchased Ethylphenidate, J Clin Psychopharmacol, vol.35, issue.4, pp.472-475, 2015.

C. Soussan and A. Kjellgren, Chasing the High" -Experiences of Ethylphenidate as Described on International Internet Forums, Subst Abuse, vol.9, pp.9-16, 2015.

K. H. Bennett, H. M. Hare, and R. M. Waller, Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: a retrospective cross-sectional analysis following public health interventions, BMJ Open, vol.7, p.15716, 2017.

R. Robertson, Prolonged mental health effects of ethylphenidate beyond cessation of use, Addiction, vol.112, pp.183-184, 2017.

C. Anderson, C. Morrell, and D. Marchevsky, A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia, BMJ Case Rep, 2015.

, European Monitoring Center for Drugs and Drug Addiction. EMCDDA-Europol, 2011.

, Official Journal of the European Union. Council decision, 2017.

, Ethylphenidate's report

J. H. Ho and D. M. Wood, Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance, Eur J Clin Pharmacol, vol.71, pp.1185-96, 2015.

M. Huber, E. Kirchler, and M. Karner, Delusional parasitosis and the dopamine transporter. A new insight of etiology? Med Hypotheses, vol.68, pp.1351-1359, 2007.

P. Gomez and C. , Síndrome de Ekbom en consumidor de metilfenidato intravenoso, Adicciones, 2012.

, Synthe se the matique : nouveaux produits de synthe se, Observatoire Français des Drogues et des Toxicomanies (OFDT), 2018.

, The challenge of new psychoactive substances, Global Smart Programme, United Nations Office for Drugs and Crime, pp.1-122, 2013.

. Phenethylamines-i-have, Known And Loved:A Chemical Love Story By Alexander and Ann Shulgin

, Tryptamines i Have Known And Loved: The Chemistry Continues By Alexander and Ann Shulgin

, European Monitoring Centre for Drugs and Drug Addiction, 2018.

, European Monitoring Centre for Drugs and Drug Addiction Early-warning system on new psychoactive substances -Operating guidelines. Luxembourg: Office for Official Publications of the European Communities

, New psychoactive substances in Europe. An update from the EU Early Warning System, 2015.

B. Csete, Public health and international drug policy, Lancet, 2016.

, High-risk drug use and new psychoactive substances, European Monitoring Centre for Drugs and Drug Addiction, 2017.

, Mission Interministe rielle de Lutte contre les Drogues et les Conduites Addictives (MIDELCA), 2016 -Nouveaux Produits de Synthe se -Nouvelles Substances Psychoactives (12) European Monitoring Centre for Drugs and Drug Addiction, European Monitoring Centre for Drugs and Drug Addiction, p.47, 2016.

A. Scocard, Synthetic cannabinoids: a new addiction matrix, Presse Med, vol.46, issue.1, pp.11-22, 2017.

, Drugs and the darknet: Perspectives for enforcement, research and policy, European Monitoring Centre for Drugs and Drug Addiction and Europol, 2017.

L. Karila, G. Lafaye, A. Scocard, O. Cottencin, and A. Benyamina, MDPV and ?-PVP use in humans: The twisted sisters, Neuropharm, vol.134, pp.65-72, 2018.

G. P. Bailey, J. H. Ho, and S. Hudson, Nopaine no gain: Recreational ethylphenidate toxicity, ClinToxicol, vol.53, pp.498-499, 2015.

J. H. Ho and D. M. Wood, Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance, Eur J Clin Pharmacol, vol.71, pp.1185-96, 2015.

H. J. Zhu, K. S. Patrick, and . Straughn, Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers, J Clin Psychopharmacol, vol.37, issue.4, pp.419-428, 2017.

, European Monitoring Center for Drugs and Drug Addiction. EMCDDA-Europol, 2011.

C. Lafferty and L. Smith, The experience of an increase in the injection of ethylphenidate in Lothian, Scott Med Journal, vol.61, pp.74-83, 2014.

C. Soussan and A. Kjellgren, Chasing the High" -Experiences of Ethylphenidate as Described on International Internet Forums, Subst Abuse, vol.9, pp.9-16, 2015.

, Ethylphenidate's report

P. D. Maskell, P. R. Smith, and C. R. , Seven fatalities associated with ethylphenydate, Forensic Sci Int, vol.265, pp.70-74, 2016.

C. Parks, D. Mckeown, T. , and H. J. , A review of ethylphenidate in deaths in east and west Scotland, Forensic Sci Int, vol.257, pp.203-208, 2015.

J. Krueger, H. Sachs, and . Musshoff, First detection of ethylphenidate in human fatalities after ethylphenidate intake, Forensic Sci Int, vol.243, pp.126-135, 2014.

B. Barcelo, I. Gomila, and M. C. Rotolo, Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate, Int J Legal Med, vol.2017131, issue.6, pp.1543-1553

R. Robertson, Prolonged mental health effects of ethylphenidate beyond cessation of use, Addiction, vol.112, pp.183-184, 2017.

C. Anderson, C. Morrell, and D. Marchevsky, A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia, BMJ Case Rep, 2015.

B. Pignon and B. Rolland, Dependence on Internet-Purchased Ethylphenidate, J Clin Psychopharmacol, vol.2015, issue.4, pp.472-475

A. Scocard and M. Fatseas, Addiction to Ethylphenidate with Ekbom syndrome: a case report

O. Cottencin, B. Rolland, and L. Karila, New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature, European Drug Report, vol.20, issue.32, pp.4106-4111, 2014.

. Neptune, Novel Psychoactive Treatment : UK network

C. Miliano, D. Luca, and M. A. , Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants, Front Neurosci, vol.10, p.153, 2016.

L. Karila, Synthetic cathinones: a new public health problem, Curr. Neuropharmacol, vol.13, issue.1, pp.12-20, 2015.

W. M. Compton and . Pharm, Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States, American Journal of Psychiatry